204 related articles for article (PubMed ID: 38535033)
1. Pulmonary Adverse Events in Cancer Immunotherapy: Case Studies of CT Patterns.
Bocchini G; Imperato MC; Valente T; Guarino S; Lieto R; Massimo C; Muto E; Romano F; Scaglione M; Sica G; Vitagliano Torre D; Masala S; Bocchino M; Rea G
Diagnostics (Basel); 2024 Mar; 14(6):. PubMed ID: 38535033
[TBL] [Abstract][Full Text] [Related]
2. Expected and non-expected immune-related adverse events detectable by CT.
Ciccarese F; Piccinino A; Brocchi S; Balacchi C; Dall'Olio FG; Massari F; Rihawi K; Paccapelo A; Ardizzoni A; Golfieri R
Eur J Radiol; 2021 May; 138():109617. PubMed ID: 33676358
[TBL] [Abstract][Full Text] [Related]
3. Pulmonary Toxicities of Immunotherapy.
Altan M; Zhong L; Shannon VR; Sheshadri A
Adv Exp Med Biol; 2021; 1342():357-375. PubMed ID: 34972974
[TBL] [Abstract][Full Text] [Related]
4. Radiological assessment of immunotherapy effects and immune checkpoint-related pneumonitis for lung cancer.
Hu Q; Wang S; Ma L; Sun Z; Liu Z; Deng S; Zhou J
J Cell Mol Med; 2023 Jul; 28(5):e17895. PubMed ID: 37525480
[TBL] [Abstract][Full Text] [Related]
5. Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis.
Huang A; Xu Y; Zang X; Wu C; Gao J; Sun X; Xie M; Ma X; Deng H; Song J; Ren F; Pang L; Qian J; Yu Z; Wan S; Chen Y; Pan L; Zhuang G; Liu S; Xue X
BMC Cancer; 2021 May; 21(1):634. PubMed ID: 34051746
[TBL] [Abstract][Full Text] [Related]
6. Immune-Related Adverse Events: Pneumonitis.
Jain A; Shannon VR; Sheshadri A
Adv Exp Med Biol; 2018; 995():131-149. PubMed ID: 30539509
[TBL] [Abstract][Full Text] [Related]
7. Immune-Related Adverse Events: Pneumonitis.
Zhong L; Altan M; Shannon VR; Sheshadri A
Adv Exp Med Biol; 2020; 1244():255-269. PubMed ID: 32301020
[TBL] [Abstract][Full Text] [Related]
8. Pulmonary adverse events due to immune checkpoint inhibitors: A literature review.
Georgakopoulou VE; Garmpis N; Mermigkis D; Damaskos C; Chlapoutakis S; Mantzouranis K; Gkoufa A; Papageorgiou C; Garmpi A; Makrodimitri S; Diamantis E; Sklapani P; Trakas N; Tsiafaki X
Monaldi Arch Chest Dis; 2021 Oct; 92(2):. PubMed ID: 34634898
[TBL] [Abstract][Full Text] [Related]
9. Immune-related adverse events on body CT in patients with small-cell lung cancer treated with immune-checkpoint inhibitors.
Park H; Hatabu H; Ricciuti B; Aijazi SJ; Awad MM; Nishino M
Eur J Radiol; 2020 Nov; 132():109275. PubMed ID: 32949913
[TBL] [Abstract][Full Text] [Related]
10. A Novel Workflow to Create a Checkpoint Inhibitor Pneumonitis Patient Registry.
Faucheux A; Olson E; Lantz J; Roberts N; Aggarwal V; Newman I; Ponnatapura J; Lycan T
Cureus; 2023 Feb; 15(2):e34683. PubMed ID: 36909081
[TBL] [Abstract][Full Text] [Related]
11. [Adverse effects of immunotherapy : Clinical aspects, radiological and nuclear medicine results].
Widmann G; Nguyen VA; Plaickner J; Jaschke W
Radiologe; 2017 Oct; 57(10):840-849. PubMed ID: 28733704
[TBL] [Abstract][Full Text] [Related]
12. [Immune-related pneumonitis: A differential diagnosis of SARS-CoV-2 pneumonia].
Nigen B; Chéné AL; Liberge R; Sagan C; Blanc FX
Rev Mal Respir; 2022 Sep; 39(7):626-632. PubMed ID: 35906150
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular, Renal and Pulmonary Toxicity of Immune Checkpoint Inhibitors in Cancer: What the GP Should Know.
Smekens L; Genoud V; Usdin N; Ben Aïssa A
Praxis (Bern 1994); 2023; 112(3):160-171. PubMed ID: 36855889
[No Abstract] [Full Text] [Related]
14. Case report: Pneumonia with clinical symptoms precedes imaging evidence after immune checkpoint inhibitors combined with radiotherapy in lung squamous cell cancer.
Wang Y; Wang Y; Yu J; Meng X
Front Immunol; 2022; 13():998516. PubMed ID: 36189237
[TBL] [Abstract][Full Text] [Related]
15. Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non-Small-Cell Lung Cancer.
Naidoo J; Nishino M; Patel SP; Shankar B; Rekhtman N; Illei P; Camus P
Clin Lung Cancer; 2020 Sep; 21(5):e435-e444. PubMed ID: 32576443
[TBL] [Abstract][Full Text] [Related]
16. Imaging assessment of toxicity related to immune checkpoint inhibitors.
Berz AM; Boughdad S; Vietti-Violi N; Digklia A; Dromain C; Dunet V; Duran R
Front Immunol; 2023; 14():1133207. PubMed ID: 36911692
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: Focus on Nivolumab.
Bukamur H; Katz H; Alsharedi M; Alkrekshi A; Shweihat YR; Munn NJ
South Med J; 2020 Nov; 113(11):600-605. PubMed ID: 33140115
[TBL] [Abstract][Full Text] [Related]
18. Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis.
Wang H; Guo X; Zhou J; Li Y; Duan L; Si X; Zhang L; Liu X; Wang M; Shi J; Zhang L
Thorac Cancer; 2020 Jan; 11(1):191-197. PubMed ID: 31762218
[TBL] [Abstract][Full Text] [Related]
19. Immune-related organizing pneumonitis in non-small cell lung cancer receiving PD-1 inhibitor treatment: A case report and literature review.
Yin B; Xiao J; Li J; Liu X; Wang J
J Cancer Res Ther; 2020; 16(7):1555-1559. PubMed ID: 33565499
[TBL] [Abstract][Full Text] [Related]
20. Are immune checkpoint inhibitors safe and effective in lung cancer patients with pre-existing interstitial lung disease?
Zhu L; Gao R; Li H; Zheng Y; Yang J
Immunotherapy; 2024 Apr; 16(7):465-480. PubMed ID: 38511241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
